그리니치 라이프사이언시스 (GLSI) 주가

그리니치 라이프사이언시스(GLSI)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $18.99 (+3.26%), 시가총액 $378.51M, 52주 범위 $7.85 ~ $33.57.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc.

핵심 지표

• 현재가: $18.99 (+3.26%)
• 시가총액: $378.51M
• 52주 최저~최고: $7.85 ~ $33.57
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

그리니치 라이프사이언시스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

그리니치 라이프사이언시스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 매수 (4.0 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 172.72
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문